Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 13,967 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: combined treatment Clear all
Active, not recruiting Phase 2 Interventional

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

NCT05419011
View directory record Official record
Conditions
Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 17, 2026, 10:43 AM EDT
Not listed Phase 4 Interventional

COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study

NCT05724771
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)
Drug
Lead sponsor
Chicago Headache Center & Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

NCT04246671
View directory record Official record
Conditions
Chordoma, HER2-positive Breast Cancer
Interventions
TAEK-VAC-HerBy
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

NCT04055844
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, Myelodysplastic Syndromes
Interventions
Decitabine, Ruxolitinib, Donor Lymphocyte Infusion (DLI)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
12 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 17, 2026, 10:43 AM EDT
Terminated Phase 4 Interventional Results available

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

NCT01100437
View directory record Official record
Conditions
Chronic Pain
Interventions
EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

NCT01460537
View directory record Official record
Conditions
Neoplasms
Interventions
Gemcitabine, BAY80-6946, Cisplatin, NaCl, BAY80-6964 fixed dose
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Tampa, Florida • Rochester, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 17, 2026, 10:43 AM EDT
Recruiting Phase 2 Interventional

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

NCT02393157
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Interventions
Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 31 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 17, 2026, 10:43 AM EDT
Recruiting Phase 2 Interventional

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

NCT07321912
View directory record Official record
Conditions
Osteosarcoma, Ewing Sarcoma
Interventions
Eflornithine, Topotecan, Cyclophosphamide, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Cisplatin, Methotrexate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
0 Years to 50 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Tampa, Florida • Portland, Oregon • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 1 Interventional

Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia

NCT00643981
View directory record Official record
Conditions
Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis, Coronary Arteriosclerosis
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Not applicable Interventional

Treatment of Low Metabolic Rate Following Bariatric Surgery

NCT01596907
View directory record Official record
Conditions
Morbid Obesity
Interventions
Ephedrine sulfate with caffeine, cellulose
Drug
Lead sponsor
Oregon Weight Loss Surgery, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Beaverton, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide for Patients With Myelofibrosis (MF)

NCT00352794
View directory record Official record
Conditions
Myelofibrosis
Interventions
Lenalidomide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 17, 2026, 10:43 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes

NCT04057677
View directory record Official record
Conditions
Type 2 Diabetes, Muscular Atrophy, Sedentary Behavior, Exercise, Pre-diabetes
Interventions
Bed Rest Intervention, Exercise Program
Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
60 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 17, 2026, 10:43 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 81 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 10:43 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

NCT05303792
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin
Drug · Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
50 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
71
States / cities
Birmingham, Alabama • Irvine, California • Orange, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Not applicable Interventional

The Combined Aerobic Exercise and Cognitive Training (ACT) Trial: The ACT Trial

NCT03313895
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aerobic & Cognitive Training (ACT), Cycling Only, Cognitive Training Only, Stretching and Mental Stimulating Activities
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
65 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Stanford, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 4 Interventional Results available

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

NCT02045875
View directory record Official record
Conditions
Asthma
Interventions
Dulera
Drug
Lead sponsor
Asthma Management Systems
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 17, 2026, 10:43 AM EDT
Active, not recruiting Phase 2 Interventional

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

NCT01750281
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
13
States / cities
Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 17, 2026, 10:43 AM EDT
Terminated Not applicable Interventional Results available

Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery

NCT01558128
View directory record Official record
Conditions
Cardiac Disease
Interventions
Amiodarone, Cardioversion
Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 17, 2026, 10:43 AM EDT
Not yet recruiting Phase 4 Interventional

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

NCT07187466
View directory record Official record
Conditions
Overactive Bladder, Parkinson Disease
Interventions
mirabegron, Exercise-based behavioral therapy
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Decatur, Georgia • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation and Androgen Ablation for Prostate Cancer

NCT01517451
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Radiation Therapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 10:43 AM EDT
Terminated Phase 4 Interventional Results available

Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery

NCT03115151
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine, Hydromorphone, Fentanyl
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 17, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma

NCT00059839
View directory record Official record
Conditions
Lymphoma
Interventions
doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 17, 2026, 10:43 AM EDT
Terminated Phase 2 Interventional Results available

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

NCT03382912
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pegilodecakin, Nivolumab
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Tempe, Arizona • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 17, 2026, 10:43 AM EDT